Pfizer, Inc.
Key numbers
What the whole company is worth on the stock market.
Price ÷ last year's profit per share. Higher means investors pay more for each $1 of profit.
The same ratio using next year's expected profit.
How much the stock swings compared with the market: 1 moves like the market, 1.5 moves 50% more.
Yearly dividend as a share of the price.
What analysts say
28 analysts
Recent analyst actions
Financial health
Nine checks of profitability, debt and efficiency. 7–9 strong, 4–6 average, 0–3 weak.
Profitability and debt
Short-term assets ÷ short-term debts. Below 1 means more due within a year than on hand.
Fair value (DCF model)
A discounted-cash-flow model: what future cash flows are worth today. It is a model, not a promise.
Compared with similar companies
The company next to its sector peers.
| Company | Price | P/E | P/B | Market value |
|---|---|---|---|---|
| LLYEli Lilly and Company | 1,181.78 | 41.6 | 38.3 | $1.11T |
| JNJJohnson & Johnson | 262.28 | 29.9 | 6.1 | $630.04B |
| ABBVAbbVie Inc. | 279.11 | 77.4 | 94.4 | $488.55B |
| MRKMerck & Company, Inc. | 145.41 | 113.2 | 5.0 | $359.22B |
| UNHUnitedHealth Group Incorporated | 377.77 | 24.1 | 3.2 | $340.46B |
| TMOThermo Fisher Scientific Inc | 659.21 | 34.9 | 4.1 | $243.30B |
| AMGNAmgen Inc. | 415.59 | 25.7 | 20.4 | $224.29B |
| ABTAbbott Laboratories | 100.68 | 31.8 | 4.2 | $172.35B |
| PFEPfizer, Inc. | 28.38 | 37.2 | 1.6 | $161.19B |
| BMYBristol-Myers Squibb Company | 57.14 | 13.0 | 5.9 | $120.77B |
| Sector average | 42.9 | 18.3 |
About the company
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobuli…
Data: Elcaro Core (Yahoo Finance, Binance, Treasury) · Information, not investment advice.